Medication repurposing in pediatric patients: Teaching old drugs new tricks

Journal of Pediatric Pharmacology and Therapeutics

Volumn 21, Issue 1, 2016, Pages 36-53

  Rumore, Martha M ^a,b  

^a TOURO COLLEGE   (United States)

^b LLP ^*  (United States)

Author keywords

Drug information services; Drug repositioning; Drug utilization; Off label use; Pediatrics; Unlabeled indication

Indexed keywords

EID: 85019387894     PISSN: 15516776     EISSN: 2331348X     Source Type: Journal    
DOI: 10.5863/1551-6776-21.1.36     Document Type: Article

References (164)

1. Statement of Harry C. Shirkey, MD at the Conference of Professional and Scientific Societies, Commission on Drug Safety. 1963.
2. Shah SS, Hall M, Goodman DM, et al. Offlabel drug use in hospitalized children. Arch Peds Adol Med. 2007;161(3):282-290.
3. Turner S, Longworth A, Nunn AJ, et al. Unlicensed and off label drug use in paediatric wards: prospective study. Br Med J. 1998;316(7128):343-345.
4. Best Pharmaceuticals for Children Act. P.L. 107-109 (2002).
5. Pediatric Research Equity Act. P.L. 108-155 (2003).
6. Food and Drug Administration Safety and Innovation Act. P.L. 112-144 (2012).
7. Sachs AN, Avant D, Lee CS, et al. Pediatric information in drug labeling. JAMA. 2012;307(18):1914-1915.
8. Rivera DR, Hartzema AG. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development. Ann Pharmacother. 2014;48(3):369-379.
9. Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discovery Today. 2014. http://dx.doi.org/10.1016/j.drudis.2013.11.005. Accessed July 22, 2015.
10. Orphan Drug Act. P.L. 97-414 (1983).
11. Food, Drug Cosmetic Act. U.S.C. 21 §§301-97 (1938).
12. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther. 2012;91(5):796-801.
13. ‘T Jong GW, Vulto AG, de Hoog M. A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics. 2001;108(5):1089-1093.
14. Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of “off-label” and unlicensed drugs in a pediatric intensive care unit. Lancet. 1996;347(9000):549-550.
15. Craig JS, Henderson CR, Magee FA. The extent of unlicensed and off-label drug use in the paediatric ward of a district general hospital in Northern Ireland. Ir Med J. 2001;94(8):237-240.
16. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child. 2000;83(6):498-501.
17. US Food and Drug Administration. New Pediatric Labeling Information Database. http://www.accessdata.fda.gov/scripts/sda/sdnavigation.cfm?sd=labelingdatabase.pdf. Accessed July 22, 2015.
18. US Food and Drug Administration. Rare Disease Repurposing Database. http://www.fda.gov/ForIndustry/Developing-ProductsforRareDiseasesConditions/. Accessed July 23, 2015.
19. Generali JA, Cada DJ, editors. Off-Label Drug Facts. Facts & Comparisons Publishing Group, Wolters Kluwer Health; 2014.
20. Custer J, Rau R, editors. The Johns Hopkins Hospital Harriet Lane Handbook. 20th ed. Philadelphia, PA: Elsevier Mosby; 2014.
21. Houst B, Rumore MM. Development of a Pediatric Specific Medication Resource Center at a Metropolitan Children’s Hospital. Poster Presentation. American Pharmacist’s Association. March 1-4, 2013, Los Angeles, CA. J Amer Pharm Assoc. 2013;53(2):78.
22. Lohr KN. Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care. 2004;16(1):9-18.
23. Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2012;78(24):1974-1980.
24. Madenci E, Yilmazk K, Yilmazk M, et al. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol. 2006;12(2):53-56.
25. Ward LM, Raunch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab. 2011;96(2):355-364.
26. App EM, King M, Helfesrieder R, et al. Acute and long term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Amer Rev Resp Dis. 1990;141(3):605-612.
27. Eleftheriou D, Levin M, Shingadia D, et al. Management of Kawasaki’s disease. Arch Dis Child. 2014;99(1):74-83.
28. Omari TI, Benninga MA, Sansom L, et al. Effect of baclofen on esophagogastric motility and gastrointestinal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr. 2006;149(4):468-474.
29. El Shaded A, Dargarville P, Ohlsson A, Soll RF. Surfactant for meconium aspiration syndrome in full term infants. Cochrane Database Syst Rev. 2007;3:CD002054.
30. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.
31. Furuta GT, Liacouras CA, Collins MH, et al. First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterol. 2007;133(4):1342-1363.
32. Lemonnier E, Degrez C, Phelep M, et al. A randomized controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry. 2012(2):e202. http://www.nature.com/tp/journal/v2/n12/pdf/tp2012124a.pdf. Accessed July 23, 2015.
33. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-2121.
34. Mueni E, Opiyo N, English M. Caffeine for the management of apnea in preterm infants. Int Health. 2009;1(2):190-195.
35. Rhein L, Dobson NR, Darnell RA, et al. Effects of caffeine on intermittent hypoxia in infants born prematurely: a randomized clinical trial. JAMA Pediatr. 2014;168(3):250-257.
36. Takeuchi A, Tsuchiya H, Yamamoto N, et al. Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcomes. Anticancer Res. 2007;27(5B):3489-3496.
37. Richmond EJ, Rogol AD. Growth hormone deficiency in children. J Pituitary Soc. 2008;11(2):115-120.
38. Gil-Ad E, Topper E, Laron Z. Oral clonidine as a growth hormone stimulation test. Lancet. 1979;314(8137):278-280.
39. Rotig A, Mollet J, Rio M, Munnich A. Infantile and pediatric deficiency diseases. Mitochondrion. 2007;7(suppl):S112-S121.
40. Parikh S, Saneto R, Falk MJ, et al. A modern approach to the treatment of mitochondrial disease. Curr Treat Options Neurol. 2009;11(6):414-430.
41. Yazigi A, Abou-Charaf LC. Colchicine for recurrent pericarditis in children. Acta Paediatr. 1998;87(5):603-604.
42. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med.1983;308(23):1396-1399.
43. Choodhry VP, Ahlawat S, Pati HP, Kashyap R. Vinblastine and danazol therapy in steroid resistant childhood chronic idiopathic thrombocytopenic purpura. Internat J Hematol. 1995;61(3):157-162.
44. Hedlund-Treutiger I, Henter JI, Elinder G. Randomized study of IVIG and high dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25(2):139-144.
45. Neunert C, Lim W, Crowther M, et al. American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
46. Zheng JW, Zhou Q, Yang XJ, et al. Treatment guideline for hemangiomas and vascular malformations of the head and neck. Head Neck. 2010;32(8):1088-1098.
47. Yang Y, Sun M, Cheng X, et al. Bleomycin A5 plus dexamethasone for control of growth in infantile parotid hemangiomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(1):62-69.
48. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;5:CD004863.
49. Sahni J, Phelps SJ. Nebulized furosemide in the treatment of bronchopulmonary dysplasia in preterm infants. J Pediatr Pharmacol Ther. 2011;16(1):14-22.
50. Prabhu VG, Keszler M, Dhanireddy R. Pulmonary function changes after nebulized and intravenous furosemide in ventilated premature infants. Arch Dis Child Fetal Neonatal Ed. 1997;77(1):32-35.
51. Moody K, Siegal L, Scharbach K, et al. Pediatric palliative care. Prim Care Clin Office Pract. 2011;38:327-361.
52. Kim IK, Phrampus E, Sikes K, et al. Helium-oxygen therapy for infants with bronchiolitis. Arch Pediatr Adolesc Med. 2011;165(12):1115-1122.
53. Heyman E, Morag I, Batash D, Keidar R, et al. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatr. 2003;112:354-358.
54. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Library. 2013;4:1-153. http://www.thecochranelibrary.com. Accessed July 23, 2015.
55. Johnston P, Gillam-Krakauer M, et al. Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit. Clinics Perinatol. 2012;39(1):111-136.
56. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low-dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereal Leprol. 2005;71(6):398-400.
57. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, et al. A systematic review of treatment of drug-induced Stevens-Johnson Syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011;18(1):121-133.
58. Pinto N, Cipkala DA, Ladd PE, Pu Y, Cohn SL. Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014;61(6):1104-1106.
59. Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007;119(6):1239-1247.
60. Chen S, Lu K, Sun H. Randomized placebocontrolled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol. 2006;17(1):49-54.
61. Ballard RA, Truog WE, Cnaan A, et al. NO CLD Study Group. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006;355(4):343-353.
62. Mercier JC, Hummier H, Durrmeyer X, et al. EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies: a randomized controlled trial. Lancet. 2010;376(9738):346-354.
63. Fenichel GM, Griggs RC, Kissel J, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001;56(8):1075-1079.
64. Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine vs ketorolac. Ann Emerg Med. 2004;43(2):256-262.
65. Hagman J, Gralla J, Siegal E, et al. A doubleblind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa. J Am Acad Child Adol Psy. 2011;50(9):915-924.
66. Joung KH, Cho SC. The effect of sucrose on infants during a painful procedure. Korean J Pediatr. 2010;53(8):790-794.
67. Anand KJ. International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. Arch Pediatr Adoles Med. 2001;155(2):173-180.
68. Lazzerini M, Martelossi S, Magazzu G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease. A randomized clinical trial. JAMA. 2013;310(20):2164-2173.
69. Felipez LM, Gokhale R, Tierney MP, Kirschner BS. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr. 2012;54(4):28-33.
70. Galeotti C, Boucheron A, Guillaume S, Kone-Paut I. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody. Mol Cancer Ther. 2012;11(8):1623-1626.
71. Winner P, Pearlman EM, Linder SL, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebocontrolled trial. Headache. 2005;45(10):1304-1312.
72. Lakshmi CU, Singhi P, Malhi P, Ray MJ. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo controlled trial. Child Neurol. 2007;22(7):829-835.
73. Rumore MM. Vitamin A as an immunomodulating agent. Clin Pharm. 1993;12(7):506-514.
74. American Academy of Pediatrics Committee on Infectious Diseases: Vitamin A treatment of measles. Pediatrics. 1993;91(5):1014-1015.
75. Gabbay MA, Sato MN, Finazzo C, et al. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and the decline of residual B-cell function in new onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med. 2012;166(7):601-607.
76. Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systemic review and meta-analysis. Arch Dis Child. 2008;43(9):1093-1098.
77. Marchisio P, Consonni D, Baggi E, et al. Vitamin D supplementation reduces the risk of otitis media in otitis-prone children. Ped Infect Dis J. 2013;32(10):1055-1060.
78. Milgrom P, Ly KA, Tut OK, et al. Xylitol pediatric topical oral syrup to prevent dental caries. Arch Pediatr Adolesc Med. 2009;163(7):601-607.
79. Apt W, Aquilera X, Arribada A, et al. Treatment of chronic Chagas’ disease with itraconazole and allopurinol. Amer J Trop Med. 1998;59(1):133-138.
80. Vargus SL, Rodriguiz J. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and presentation of electrocardiographic abnormalities during 9 years of follow-up. Amer J Trop Parasitol. 2003;97(1):23-29.
81. Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache. 2004;44(3):230-237.
82. Rino PB, Scolnik D, Fustinana A, Mitelpunkt A, Glatstein M. Ascorbic acid for the treatment of methemoglobinemia: the experience of a large tertiary care pediatric hospital. Amer J Ther 2014. Published ahead of print. PMID:24914501. http://www.ncbi.nlm.nih.gov/pubmed/24914501. Accessed July 22, 2015.
83. Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Brit J Ophthalmol. 2011;95(2):209-213.
84. Kanellopoulos A, Mavrogenis AF, Mitsiokapa EA, et al. Long lasting benefits following the combination of static night upper extremity splinting with botulinum toxin A injections in cerebral palsy children. Eur J Phys Rehabil Med. 2009;45(4):501-506.
85. Coutinho dos Santos LH, Rodrigues DC, Simoes de Assis TR, Bruck I. Effective results with botulinum toxin in cerebral palsy. Pediatr Neurol. 2011;44(5):357-363.
86. Gordon CT, Cotelingam GM, Stager S,. A double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. J Clin Psy. 1995;56(6):238-242.
87. Ingrassia A, Turk J. The use of clonidine for severe and intractable sleep problems in children with neurodevelopment disorders. Eur Child Adolesc Psychiatry.2005;14(1):34-40.
88. Prince JB, Wilens TE, Biederman J, et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psy. 1996;35(5):599-605.
89. Phua E, Lopez X, Ramus J, Goldfine AB. Cromolyn Sodium for insulin-induced lipoatrophy: old drug, new use. Diabetes Care. 2013;36(12):e204-e205. http://care.diabetesjournals.org/content/36/12/e204.full.pdf+html. Accessed July 23, 2015.
90. Dawson GS, Seidman P, Ramadan HH. Improved postoperative pain control in pediatric adenotonsillectomy with dextromethorphan. Laryngoscope. 2001;111(7):1223-1226.
91. Sui A, Drachtman R. Dextromethorphan: a review of N-Methyl D-Aspartate receptor antagonist in the management of pain. CNS Drug Rev. 2007;13(1):96-106.
92. Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity. JAMA Pediatr. 2013;167(4):355-360.
93. Kelly AS, Metziq AM, Rudser KD, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity. 2012;20(2):364-370.
94. Kallepalli BJ, Bhatara VS, Fogas BS, et al. Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. J Child Adol Psychopharm. 1997;7(2):97-107.
95. Wheeler DS, Vaux KK, Tam DA. Use of gabapentin in the treatment of childhood reflex sympathetic dystrophy. Pediatr Neurol. 2000;22(3):220-221.
96. Eiland LS, Jenkins LS, Durham SH. Pediatric migraine: pharmacologic agents for prophylaxis. Ann Pharmacother. 2007;41(7):1181-1190.
97. Robinson AA, Malow BA. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013;28(12):1618-1621.
98. Mokhtar GM, Shaaban SY, Elbarbary NS, Fasyed WA. A trial to access the efficacy of glutamic acid in prevention of vincristineinduced neurotoxicity in pediatric malignancies: a pilot study. J Pediatr Hem/Onc. 2010;32(8):594-600.
99. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074.
100. Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol. 2002;25(6):325-332.
101. Florin TA, Shaw KN, Kittick M, et al. Nebulized hypertonic saline for bronchiolitis in the emergency department. A randomized clinical trial. JAMA Pediatr. 2014;168(7):664-670.
102. Wu S, Baker C, Lang ME, et al. Nebulized hypertonic saline for bronchiolitis. A randomized clinical trial. JAMA Pediatr. 2014;168(7):657-663.
103. Rodriguiz V, Lee A, Witman PM, Anderson PA. Kasabach-Merritt phenomenon: case series and retrospective review of the Mayo Clinic experience. J Pediatr Hematol Oncol. 2009;31(7):522-526.
104. Kim EH, Kyung NK, Park M, et al. Clinical features of infantile hepatic hemangioendothelioma. Korean J Pediatr.2011;54(6):260-266.
105. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326(22):1456-1463.
106. Johnston RG, Noseworthy TW, Friesen EG, et al. Isoflurane therapy for status asthmaticus in children and adults. Chest. 1990;97(3):698-701.
107. Shankar V, Churchill KB, Deshpande JK. Isoflurane therapy for severe refractory status asthmaticus in children. Intensive Care Med. 2006;32(6):927-933.
108. Wickman S, Siplia I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomized controlled trial. Lancet. 2001;357(9270):1743-1748.
109. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache. 2004;44(3):238-243.
110. Winter SC. Plasma carnitine deficiency. Amer J Dis Child.1987;141(6):660-665.
111. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168(2):178-184.
112. Tofil NM, Benner KW, Faro SJ, Winkler MK. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Ped Crit Care Med. 2008;7(3):252-254.
113. Glare PA, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. Drugs. 2008;68(18):2575-2590.
114. Glorieux FH, Bishop NJ, Plotkin H, et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339(14):947-952.
115. Salehpour S, Tauakkoli S. Cyclic pamidronate therapy in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2010;23(1-2):73-80.
116. Sung V, Collett S, deGooyer T, et al. Probiotics to treat or prevent excessive infant crying: systemic review and meta-analysis. JAMA Pediatr. 2013;167(12):1150-1157.
117. Hao Q, Lu Z, Dong BR, Huang CQ, Wu T. Probiotics for preventing acute respiratory tract infections. Cochrane Database Syst Rev. 2011;9:CD006895.
118. Parodi E, Rivetti E, Amenlola G, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Brit J Hematol. 2009;144(4):552-558.
119. DelVecchio G, DeSantis A, Accettura L, et al. Chronic immune thrombocytopenia in childhood. Blood Coag Fibrolysis. 2014;25(4):297-299.
120. Senniappan S, Alexandrescu S, Tatevian N, et al. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med. 2014;370(12):1131-1137.
121. Van Hove JK, Kerckhove KV, Hennermann JB, et al. Benzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis. 2005;28(5):651-663.
122. Arnold GL, Griebel ML, Valentine JL, Koroma DM, Kearns GL. Dextromethorphan in nonketotic hyperglycemia: metabolic variation confounds the dose-response relationship. J Inherit Metab Dis. 1997;20(1):28-38.
123. Brock PR, Knight KR, Freyer DR. Platinuminduced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new international society of pediatric oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408-2417.
124. Neuwelt EA, Gilmer-Knight K, Lacy C, et al. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with bloodbrain-barrier disruption. Pediatr Blood Cancer. 2006;47(2):174-182.
125. Laue L, Jones J, Barnes KM, Cutler GB. Treatment of familial male precocious puberty with spironolactone, testosterone, and deslorelin. J Clin Endocrinol Metab.1993;76(1):151-155.
126. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with the addition of deslorelin after central puberty onset. J Clin Endocrinol Metab.1999;84(1):175-178.
127. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH. McCune-Albright Study Group. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr. 2003;143(1):60-66.
128. Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol. 2008;23(4):435-437.
129. Magge H, Sprinz P, Adams WG, et al. Zinc protoporphyrin and iron deficiency screening trends and therapeutic response in urban pediatric center. JAMA Pediatr. 2013;167(4):361-367.
130. Hammerman C, Bin-Nun A, Markovitch E, et al. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011;128(6):1618-1621.
131. Amendola G, Cirillio G, Spieze M, DiConcillo R, Rolando P. Treatment of childhood chronic idiopathic thrombocytopenia purpura with ascorbate. Clin Pediatr. 1995;34(5):268-370.
132. Jubelirer SJ. Pilot study of ascorbic acid for the treatment of refractory immune thrombocytopenic purpura. Am J Hematol. 1993;43(1):44-46.
133. Geobel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Brit J Ophthalmol. 2011;95(2):209-213.
134. Sulheim D, Fagermoen E, Winger A, et al. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome. JAMA Pediatr. 2014;168(4):351-360.
135. Treem WR, Hyams JS. Cyclosporine therapy for gastrointestinal disease. J Ped Gastroent Nutr. 1994;18(3):270-278.
136. Treem WR, Cohen J, Davis PM, et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum. 1999;38(5):474-479.
137. Seidman EG, Lacaille F, Russo P, Galeano N. Successful treatment of autoimmune enteropathy with cyclosporine. J Pediatr. 1999;117(6):925-932.
138. Gerloni V, Cimaz R, Gattinara M, et al. Efficacy and safety profile of cyclosporine A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatol. 2001;40(8):907-913.
139. Hauer J, Mackey D. Treatment of gabapentin associated with resolution of apnea in two infants with neurological impairment. J Palliat Med. 2013;16(4):455-458.
140. Pistoia F, Conson M, Sara M. Opsoclonus-Myoclonus Syndrome in patients with locked-in syndrome: a therapeutic porthole with gabapentin. Mayo Clin Proc. 2001;85(6):527-531.
141. Coakley JH, Moorcraft J, Hipkin LJ, Smith CS, Griffiths RD, Edwards RT. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psy. 1988;51(12):1551-1557.
142. Griggs RC, Moxley RT, Mendell JR, et al. Randomized, double-blind trial of mazindol in Duchenne dystrophy. Muscle Nerve. 1990;13(2):1169-1173.
143. Bhalla T, Sawardekar A, Russell H, Tobias JD. The role of methylene blue in the pediatric patient with vasoplegic syndrome. World J Ped Congenital Heart Surg. 2011;2(4):652-655.
144. Flynn BC, Sladen RN. The use of methylene blue for vasodilatory shock in pediatric lung transplant patient. J Cardiothor Vasc Anesth. 2009;23(4):529-530.
145. Karabulut R, Karakus C, Hirfanoglu L, et al. Treatment of postoperative enterocutaneous fistulas with octreotide in two neonates. Eur J Pediatr Surg. 2008;18(1):56-58.
146. Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychol. 1999;11(4):233-236.
147. Boyd A, Dworzynski K, Howell P. Pharmacological agents for developmental stuttering in children and adolescents: a systematic review. J Clin Psychopharmacol. 2011;31(6):740-744.
148. Holbrook T, Keet C, Frischmeyer-Guerrerio PA, et al. Use of ondansetron for food protein-induced enterocolitis syndrome. J Allergy Clin Immunol. 2013;132(5):1219-1220.
149. Freedman SB, Hall M, Shah SS, et al. Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis. JAMA Pediatr. 2014;168(4):321-329.
150. Frigon C, Desparmet J. Ondansetron treatment in a child presenting with chronic intractable pruritus. Pain Res Manag. 2006;11(4):245-247.
151. Feng J, Sethi A, Reyes-Mugica M, Antaya R. Life-threatening blood loss from scratching provoked by pruritus in the bulky perineal nevocytoma variant of giant congenital melanocytic nevus in child. J Am Acad Dermatol. 2005;53(2)(suppl 1):S139-S142.
152. Van Wattum PJ. Stuttering improved with risperidone. J Amer Acad Child Adol Psychiat. 2006;45(2):133.
153. Costa AD, Kroll RM. Sertraline in stuttering. J Clin Psychopharm. 1995;15(6):443-444.
154. Schmitt B, Martin F, Critelli H, Molinari L, Jenni O. Effects of valproic acid on sleep in children with epilepsy. Epilepsia. 2009;50(8):1860-1867.
155. Moore J, Lee M, Garzon M, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg. 2001;36(8):1273-1276.
156. Perez Payarols J, Pardo MJ, Gomez BC. Treatment of life-threatening infantile hemangiomas with vincristine. N Engl J Med.1995;333(1):69.
157. Blatt J, Corey SJ. Drug repurposing in pediatrics and pediatric hematology oncology. Drug Dis Today. 2013;18(1-2):4-10.
158. Laughon MM, Avant D, Tripathi N, et al. Drug labeling and exposure in neonates. JAMA Pediatr. 2014;168(2):130-136.
159. Shah SS, Hall M, Goodman DM, et al. Offlabel drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282-290.
160. Macaulay TE, Cook AM, Fink JL, Rapp RP, Vincent WR. Pharmacist’s role in facilitating evidence-based prescribing for unlabeled use of medications. Am J Health Syst Pharm. 2009;66(19):1735-1739.
161. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-683.
162. Podell LB. Legal implications of preparing and dispensing approved drugs for unlabeled indications. Am J Health Syst Pharm. 1983;40(1):111-113.
163. American Academy of Pediatrics. Policy statement. Off-label use of drugs in children. Pediatrics. 2014;133(3):563-567.
164. Liang BA, Mackey T. Reforming off-label promotion to enhance orphan disease treatment. Science. 2010;327(5963):273-274.